http://surgerybook.net/

and update on monitoring of direct oral anticoagulants. Blood Res 2014;49:85–94.

144. Gabriel F, Portolés O, Labiós M, et al.; RIETE Investigators. Usefulness of thrombophilia testing in

venous thromboembolic disease: findings from the RIETE registry. Clin Appl Thromb Hemost

2013;19:42–47.

145. Schafer AI, Levine MN, Konkle BA, et al. Thrombotic disorders: diagnosis and treatment.

Hematology Am Soc Hematol Educ Program 2003:520–539.

146. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132

consecutive unselected patients with venous thromboembolism–results of the Spanish Multicentric

Study on Thrombophilia (EMET-study). Thromb Haemost 1997;77:444–451.

147. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610–619.

148. Flinn WR, McDaniel MD, Yao JS, et al. Antithrombin III deficiency as a reflection of dynamic

protein metabolism in patients undergoing vascular reconstruction. J Vasc Surg 1984;1:888–895.

149. Towne JB, Bernhard VM, Hussey C, et al. Antithrombin deficiency–a cause of unexplained

thrombosis in vascular surgery. Surgery 1981;89:735–742.

150. Pabinger I, Schneider B. Thrombotic risk of women with hereditary antithrombin III-, protein Cand protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural

Inhibitors. Thromb Haemost 1994;71:548–552.

151. Thomas RH. Hypercoagulability syndromes. Arch Intern Med 2001;161:2433–2439.

152. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Eng J Med 2001;344:1222–

1231.

153. Bick RL. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein

S defects. Hematol Oncol Clin North Am 2003; 17:9–36.

154. Tait RC, Walker ID, Reitsma PH, et al. Prevalence of protein C deficiency in the healthy

population. Thromb Haemost 1995;73:87–93.

155. Donaldson MC, Belkin M, Whittemore AD, et al. Impact of activated protein C resistance on general

vascular surgical patients. J Vasc Surg 1997;25:1054–1060.

156. de Moerloose P, Bounameaux HR, Mannucci PM. Screening test for thrombophilic patients: which

tests, for which patient, by whom, when, and why? Semin Thromb Hemost 1998;24:321–327.

157. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet 2001;109:369–384.

158. Gladson CL, Scharrer I, Hach V, et al. The frequency of type I heterozygous protein S and protein C

deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 1988;59:18–

22.

159. Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation

defects associated with inherited thrombophilia: a study of 150 families. Blood 1998;92:2353–2358.

160. Siddiqi FA, Tepler J, Fantini GA. Acquired protein S and antithrombin III deficiency caused by

nephrotic syndrome: an unusual cause of graft thrombosis. J Vasc Surg 1997;25:576–580.

161. Jennings I, Cooper P. Screening for thrombophilia: a laboratory perspective. Br J Biomed Sci

2003;60:39–51.

162. Dahlback B. Blood coagulation. Lancet 2000;355:1627–1632.

163. Cole MS, Minifee PK, Wolma FJ. Coumarin necrosis–a review of the literature. Surgery

1988;103:271–277.

164. Ridker PM, Miletich JP, Hennekens CH, et al. Ethnic distribution of factor V Leiden in 4047 men

and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305–1307.

165. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous

for factor V Leiden (activated protein C resistance). Blood 1995;85:1504–1508.

166. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Eng

J Med 1994;330:517–522.

167. Kalafatis M, Mann KG. Factor VLeiden and thrombophilia. Arterioscler Thromb Vasc Biol

1997;17:620–627.

168. Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003;101:20–30.

169. Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in

patients with an Arg506–>Gln mutation in the gene for factor V (factor V Leiden). N Eng J Med

1997;336:399–403.

165

http://surgerybook.net/

170. De Stefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis

among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N

Eng J Med 1999;341:801–806.

171. Koeleman BP, Reitsma PH, Allaart CF, et al. Activated protein C resistance as an additional risk

factor for thrombosis in protein C-deficient families. Blood 1994;84:1031–1035.

172. Koeleman BP, van Rumpt D, Hamulyák K, et al. Factor V Leiden: an additional risk factor for

thrombosis in protein S deficient families? Thromb Haemost 1995;74:580–583.

173. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the

prevention of recurrent venous thromboembolism. N Eng J Med 2003;348:1425–1434.

174. Ouriel K, Green RM, DeWeese JA, et al. Activated protein C resistance: prevalence and implications

in peripheral vascular disease. J Vasc Surg 1996;23:46–51; discussion 51–52.

175. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated

region of the prothrombin gene is associated with elevated plasma prothrombin levels and an

increase in venous thrombosis. Blood 1996;88:3698–3703.

176. Vicente V, González-Conejero R, Rivera J, et al. The prothrombin gene variant 20210A in venous

and arterial thromboembolism. Haematologica 1999;84:356–362.

177. Cumming AM, Keeney S, Salden A, et al. The prothrombin gene G20210A variant: prevalence in a

U.K. anticoagulant clinic population. Br J Haematol 1997;98:353–355.

178. Martinelli I, Sacchi E, Landi G, et al. High risk of cerebral-vein thrombosis in carriers of a

prothrombin-gene mutation and in users of oral contraceptives. N Eng J Med 1998;338:1793–1797.

179. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of

myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation

1999;99:999–1004.

180. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the G20210A mutation of the

prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol

1999;19:700–703.

181. Hillarp A, Zöller B, Svensson P, et al. The 20210 A allele of the prothrombin gene is a common risk

factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost

1997;78:990–992.

182. Ferraresi P, Marchetti G, Legnani C, et al. The heterozygous 20210 G/A prothrombin genotype is

associated with early venous thrombosis in inherited thrombophilias and is not increased in

frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418–2422.

183. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a

history of thrombosis during pregnancy and the puerperium. N Eng J Med 2000;342:374–380.

184. McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A

mutation. Arch Pathol Lab Med 2002;126:1319–1325.

185. De Stefano V, Casorelli I, Rossi E, et al. Interaction between hyperhomocysteinemia and inherited

thrombophilic factors in venous thromboembolism. Semin Thromb Hemost 2000;26:305–311.

186. den Heijer M, Blom HJ, Gerrits WB, et al. Is hyperhomocysteinaemia a risk factor for recurrent

venous thrombosis? Lancet 1995;345:882–885.

187. den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep-vein

thrombosis. N Eng J Med 1996;334:759–762.

188. den Heijer M, Keijzer MB. Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem

Lab Med 2001;39:710–713.

189. Falcon CR, Cattaneo M, Panzeri D, et al. High prevalence of hyperhomocyst(e)inemia in patients

with juvenile venous thrombosis. Arterioscler Thromb 1994;14:1080–1083.

190. Fermo I, Vigano’D’Angelo S, Paroni R, et al. Prevalence of moderate hyperhomocysteinemia in

patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747–753.

191. Simioni P, Prandoni P, Burlina A, et al. Hyperhomocysteinemia and deep-vein thrombosis. A casecontrol study. Thromb Haemost 1996;76:883–886.

192. Den Heijer M, Rosendaal FR, Blom HJ, et al. Hyperhomocysteinemia and venous thrombosis: a

meta-analysis. Thromb Haemost 1998;80:874–877.

193. Legnani C, Palareti G, Grauso F, et al. Hyperhomocyst(e)inemia and a common

methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited

166

http://surgerybook.net/